Adtec joins the Innovation Platform at LSI 2024

We look forward to participating at the Innovation Platform at the @LSI USA 2024. Our CEO, Mary McGovern, will be in the Private Partnering Area between 18-22 March 2024 meeting with exclusive Medtech and Healthtech leaders to bring the rich content of the SteriPlas Premium Cold Plasma to them.


The SteriPlas is renowned for its proven clinical efficacy destroying chronic and complicated biofilm within infected wounds and surgical site infections. Our wide clinical bibliography of 80+ clinical trials and studies ranges from diabetic foot ulcers, LVAD infections, Sternal wound infections and so on.

Delivering a unique physical mode of action during treatment, the SteriPlas dense Cold Plasma ensures the total destruction of all bacterial species protected within biofilm which would otherwise have been resistant to antibiotics. Essentially, we are saving limbs !

We have documented the cost savings benefit due to be published this year across two separate papers focused on diabetic foot ulcers and sternal wound infections.


Our purpose of the LSI Innovation Platform attendance is to seek the potential of investment to help bring our medical device to new territories that have yet to benefit from what we can offer.
Cold Plasma is changing the norm of modern medicine.

Adtec visits Taiwan for SteriPlas expansion project


Who better to facilitate the expansion of the SteriPlas Premium Cold Plasma in the SE Asia market but the leading medical distributor, SG Biomedical. Adtec Healthcare Limited joins SG Biomedical in Taiwan to complete the introduction of three SteriPlas medical devices in the leading wound care hospitals.

Over 30 patients have so far been treated ranging from Diabetic Foot Ulcers, LVAD infections, Burn wounds, Vascular and Orthopaedic wounds and so on. All patients have had chronic infection with biofilm prior to being introduced to the SteriPlas. Some wounds have been non-healing for 4 years!


We are happy to report that over continued twice weekly use over the last two months, all patients are responding very well with most having been fully healed and no relapse of infection.


If you are within the Taiwan region and you are interested to learn more, please contact us so that we may introduce you to our partner.

Adtec's World Map

Launching an innovative and unknown technology on the medical market has only been successful due to the many years of clinical evidence and trust that we have accrued. From being the first company worldwide to introduce Cold Plasma on wounds in clinical trials to now being the leading manufacturer behind the most effective Cold Plasma medical device, Adtec Healthcare Limited has the strongest experience on how to successfully combat infections stalled by biofilm.


Our global presence of the SteriPlas Premium Cold Plasma is increasing with multiple clinics and distributors endorsing our medical device for chronic infection management of wounds, surgical site infections and medical dermatology.


There are multiple clinics in each country that help to spread the word of the benefit that our medical device brings to non-healing infections. Unfortunately, there is not enough space on this small map to reflect this!


We have also significantly increased our Distributor portfolio into new countries who are rapidly bringing the SteriPlas to their clinics and customers, with plans to expand even further into new territories which we are currently working on.

To learn more about the successes of our dense and rich Cold Plasma, send us a message at We are also keen to reach out to new distributors who also wish to bring our Cold Plasma to their territories.

Effective at deep and difficult to treat infection areas


The Premium Cold Plasma from our SteriPlas can kill all bacterial species, regardless of the resistance profile or if they are protected within biofilm. Due to the dense and rich Cold Plasma created, this includes treating difficult to reach areas such as LVAD drivelines, catheters and stoma infections.

Propelled by the gas flow, the Cold Plasma will travel down the gaps around the crevices of the infected driveline until it reaches the site of biofilm which is typically deep underneath the skin fold.

The enhanced physical mode of action of the SteriPlas is delivered quickly and effectively, eradicating bacteria which would otherwise have been resistant to conventional therapies such as antibiotics. These benefits are widely documented including the safety of having no side effects associated to our reliable and consistent Cold Plasma.


The adoption of the SteriPlas has been significantly increasing across the globe for LVAD infection treatments with promising results. To learn more about the SteriPlas, send us an email at